Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Visseren

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1996
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stabilityS H van der Burg, M J Visseren, R M Brandt, et al.
Behring Institute Mitteilungen|July 1, 1994
Tumor rejection antigens and tumor specific cytotoxic T lymphocytesR E Toes, R Offringa, M C Feltkamp, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alphaW M Vuist, M J Visseren, M Otsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1995
CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cellsM J Visseren, A van Elsas, E I van der Voort, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunityM J Visseren, M Koot, E I van der Voort, et al.
International Journal of Cancer|November 5, 1997
Affinity, specificity and T-cell-receptor diversity of melanoma-specific CTL generated in vitro against a single tyrosinase epitopeM J Visseren, S H van der Burg, G E Hawes, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptideE Hooijberg, M J Visseren, P C van den Berk, et al.
International Journal of Cancer|October 23, 1997
Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene productM J Visseren, S H van der Burg, E I van der Voort, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1996
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stabilityS H van der Burg, M J Visseren, R M Brandt, et al.
Behring Institute Mitteilungen|July 1, 1994
Tumor rejection antigens and tumor specific cytotoxic T lymphocytesR E Toes, R Offringa, M C Feltkamp, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alphaW M Vuist, M J Visseren, M Otsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1995
CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cellsM J Visseren, A van Elsas, E I van der Voort, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunityM J Visseren, M Koot, E I van der Voort, et al.
International Journal of Cancer|November 5, 1997
Affinity, specificity and T-cell-receptor diversity of melanoma-specific CTL generated in vitro against a single tyrosinase epitopeM J Visseren, S H van der Burg, G E Hawes, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptideE Hooijberg, M J Visseren, P C van den Berk, et al.
International Journal of Cancer|October 23, 1997
Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene productM J Visseren, S H van der Burg, E I van der Voort, et al.
Pageof 1